Filing Flows › VitaNova Life Sciences (VNOV) › Q3 FY25
VitaNova Life Sciences (VNOV) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Mar 17, 2025
VitaNova Life Sciences (VNOV) reported revenue of $308K for the third quarter fiscal 2025 (Q3 FY25), up 12-fold from a year earlier and +6% from the quarter before. Operating margin was 35.3%, net earnings $73K (23.7% of revenue).
VitaNova Life Sciences, Q3 FY25: revenue $308K (12× year over year), operating margin 35.3%, net earnings $73K, operating cash flow $209K. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $308K | +6% | 12× |
| Gross profit | $189K | +21% | +625% |
| Operating profit | $109K | +74% | 18× |
| Net earnings | $73K | +124% | 12× |
| Operating cash flow | $209K | 24× | — |
What changed
Revenue was $308K in Q3 FY25, up 1081% year over year and up 6% from the previous quarter. Sale of Healthcare Products was the largest line at 98% of revenue.
Gross margin was 61.4%, down 38.6 points from a year earlier. Operating profit was $109K, a 35.3% margin (up 12.5 points year over year). Of the extra revenue versus a year earlier, 36% reached operating profit, above the 23% margin then. Operating expenses grew 299% against revenue growth of 1081%. Net earnings were $73K, up 1127% year over year. The effective tax rate was 32.6%.
Operating cash flow was $209K, 286% of net earnings. Non-cash charges added back $0K of share-based compensation. Working capital and other items added $135K.
Questions
What was VitaNova Life Sciences' revenue in the third quarter fiscal 2025?
VitaNova Life Sciences (VNOV) reported revenue of $308K for the third quarter fiscal 2025 (Q3 FY25), up 12-fold from a year earlier and +6% from the quarter before.
Was VitaNova Life Sciences profitable in the third quarter fiscal 2025?
Operating profit was $109K (35.3% of revenue) and net earnings $73K.